Quick Buzz Feed
Artificial Intelligence (AI), especially machine learning, is poised to transform vaccine development, dramatically reducing the time and cost involved. Researchers are leveraging AI to design broad-spectrum coronavirus vaccines and enhance the accuracy of annual flu shots, promising a future where humanity is better prepared for future pandemics.
This section highlights how machine learning aims to make drug and vaccine discovery more cost-effective and time-efficient, moving away from the current average of nearly $900 million per vaccine. Pharmaceutical giants like Pfizer, Eli Lilly, and Moderna are actively investing in AI for drug and vaccine research. While AI-discovered drugs haven't yet passed clinical trials, experts believe AI's primary benefit is in accelerating the early stages by helping researchers quickly identify and discard unsuitable candidates. For instance, AI significantly sped up the development of a broad-spectrum coronavirus vaccine by analyzing 15 million viral strains to pinpoint constant proteins for vaccine candidates, cutting the process to a third of the estimated time without AI.
The article explores AI's potential to improve existing vaccines, such as the yearly flu shot, which often struggles with effectiveness due to the flu virus's rapid mutation and the need for early strain prediction. A retrospective study showed that the machine learning algorithm, VaxSeer, was more accurate than annual WHO recommendations in predicting dominant flu strains and selecting appropriate antigenic matches. This success is attributed to its training on extensive global data, including 20 years of information from the WHO's Global Influenza Surveillance and Response System and data from the Francis Crick Institute on antibody binding.
Researchers emphasize that access to robust data is crucial for AI in vaccine development, noting challenges with proprietary data and combining diverse datasets efficiently. Inconsistent data collection and measurement methods across studies can confuse algorithms and lead to flawed results, prompting a call for standardized data annotation. Even with better data, current volumes are often insufficient for AI models to pinpoint just one or two optimal vaccine candidates, creating a bottleneck in the subsequent hands-on experimentation phase requiring physical production and animal testing of multiple options.
Progress in AI for bacterial vaccines is anticipated to be slower due to the more complex and varied immune evasion strategies employed by bacterial pathogens. Sir Andrew Pollard, working on a vaccine for Staphylococcus aureus, believes AI can be beneficial but requires larger datasets obtained from studies where healthy individuals are safely exposed to bacteria to measure their immune responses. He expects algorithms to become more sensitive over time, needing less data and potentially even being able to predict immune responses to various pathogens.
Researchers acknowledge public concerns about AI and stress that it will serve as a powerful tool rather than a complete replacement for human scientists. Human studies will always be essential to ensure vaccine safety and efficacy. While AI could potentially design clinical trials and might even reduce the reliance on animal trials by predicting vaccine outcomes more accurately, experts agree that human intellect is indispensable for navigating complex biological factors and guiding the entire vaccine development process.